Swiss pharma giant Novartis has entered into a major multiyear alliance with privately-held US cancer immunotherapy developer Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway. 30 March 2015
Share of MorphoSys fell 20% to 54.71 euros after the company revealed that US biotech firm Celgene has dropped its $818 million multiple myeloma agreement with the German group. 29 March 2015
Five new medicines have been recommended for approval at the March 2015 meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). 27 March 2015
Drugmaker Cadila Healthcare has acquired a 50% stake from fellow India-based biotech firm Bharta Serums and Vaccines in their joint venture firm-Zydus BSV Pharma, thus taking full control of the business, according to local media reports. 27 March 2015
Exclusive agreement broadens Helsinn’s existing partnerships for anamorelin in the area of cancer supportive care across multiple global territories. 26 March 2015
The National Institute of Health and Care Excellence (NICE), the medicines cost watchdog for England and Wales, today announced several National Health Service funding decisions. 25 March 2015
Lpath says that its investigational therapy Asonep (sonepcizumab) did not meet the primary endpoint in a Phase IIa trial in renal cell carcinoma, with shares falling as much as 39% on the announcement. 25 March 2015
US pharma giant Merck & Co says it will discontinue a study of its cancer drug Keytruda (pembrolizumab) on strong Phase III trials results. 24 March 2015
Japanese pharma major Astellas Pharma and US drugmaker Medivation have presented new data from the Phase II TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC). 24 March 2015
Japanese drugmaker Ono Pharmaceutical has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for its New Drug Application for the human anti-human PD-1 monoclonal antibody Opdivo (nivolumab). 24 March 2015
New findings released by Newspoll shows overwhelming support for access to new cancer medicines through the Pharmaceutical Benefits Scheme (PBS), for Australian patients. 24 March 2015
US biotech firm ImmunoGen (Nasdaq: IMGN) saw its shares leap 17% to $8.74 in early morning trading on news of a potentially lucrative deal with Japan’s largest drugmaker Takeda Pharmaceutical 23 March 2015
Reversing a previous negative opinion, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now come out in favor of now defunct Dendreon’s Provenge (sipuleucel-T) for the treatment of men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. 23 March 2015
US drugmaker AbbVie has joined forces with Russia’s R-Pharm to establish the joint production of Kaletra (lopinavir/ritonavir), a drug for the treatment of HIV, reports The Pharma Letter’s local correspondent. 21 March 2015
US pharma major Eli Lilly has joined forces with Innovent Biologics, a leading Chinese biotech firm, in a broad collaboration to bring potential oncology therapies to patients in China and elsewhere around the world. 20 March 2015
The US district court has rejected Amgen’s request for a preliminary injunction to block Sandoz’s Neupogen (fligrastim) biosimilar Zarxio (fligrastim-sndz). 20 March 2015
Nektar Therapeutics has announced that its Phase III study of NKTR-102 (etirinotecan pegol) in advanced breast cancer did not achieve statistical significance in breast cancer. 19 March 2015
Spanish pharma company Zeltia is laying the groundwork for a period of significant potential growth and value creation, according to a report from investment research company Edison, which has raised its valuation. 18 March 2015
Danish biotech company Genmab has entered into an agreement to purchase antibodies and related patents and know-how from privately-held French company iDD Biotech. 18 March 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024